ArticleHuman mutation2026
STIM1 as an Early Predictive Biomarker for Acute Respiratory Distress Syndrome (ARDS) and Its Potential Mechanisms.
Article in Human mutation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute respiratory distress syndrome (ARDS) mainly results in severe respiratory failure and significant morbidity. This study decisively investigated the effectiveness and clinical importance of stromal interaction molecule 1 (STIM1) mRNA as an early predictive biomarker for the outcomes and severity of ARDS cases. A total of 72 mechanically ventilated patients were included in the study, consisting of 51 with ARDS and 21 without. The STIM1 mRNA levels in blood and bronchoalveolar lavage fluid (BALF) from these cases were assessed by quantitative reverse transcription polymerase chain reaction (RT-qPCR). Additionally, lung tissues were collected from six patients (three with ARDS and three without) for hematoxylin-eosin staining, immunohistochemistry, and Western blot analysis. A predictive nomogram was constructed using STIM1 mRNA level and assessed for its ability to predict the severity and mortality of ARDS. A higher STIM1 mRNA level was associated with increased ARDS severity and patient mortality. Thus, STIM1 may serve as a novel biomarker for the early prediction of clinical outcomes and disease status of ARDS cases. Additionally, analysis of the GSE database revealed the MAPK signaling pathway as a key mechanism underlying the function of STIM1 in ARDS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.